MIRA Pharmaceuticals, Inc. Common Stock (MIRA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ
Market Cap: $27.73M
Last updated: Nov 17, 2026 at 11:03 AM ET
MIRA Pharmaceuticals, Inc. Common Stock (MIRA) Competitors
The companies most similar to MIRA Pharmaceuticals, Inc. Common Stock are Telomir Pharmaceuticals, Inc. Common Stock (TELO), Scilex Holding Company (SCLX) and TherapeuticsMD (TXMD). By market cap, MIRA Pharmaceuticals, Inc. Common Stock ranks 9th of the 13 companies on this page; Mereo BioPharma Group PLC ADR (MREO) is the largest at $49.11M.
Peer Comparison
MIRA's revenue growth of 0.0% is above the peer median of -0.2%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| MIRA Pharmaceuticals, Inc. Common Stock (MIRA) | $27.73M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | $36.15M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Scilex Holding Company (SCLX) | $10.06M | N/A | 0.3x | 0.0% | 143.5% | -22.8% | 0.00% |
| TherapeuticsMD Inc (TXMD) | $21.64M | N/A | 5.6x | -6.6% | N/A | -8.7% | 0.00% |
| Mereo BioPharma Group PLC ADR (MREO) | $49.11M | N/A | 61.3x | 0.0% | -116.6% | 0.0% | 0.00% |
| INmune Bio Inc (INMB) | $32.51M | N/A | N/A | 0.0% | N/A | 257.1% | 0.00% |
| Marker Therapeutics Inc (MRKR) | $14.51M | N/A | 14.5x | -245.5% | N/A | -51.0% | 0.00% |
| InspireMD Inc (NSPR) | $30.13M | N/A | 4.9x | 0.0% | -163.8% | -0.4% | 0.00% |
| Plus Therapeutics Inc (PSTV) | $26.64M | N/A | 2.0x | -230.2% | -827.8% | -2.9% | 0.00% |
| ImageneBio, Inc. (IMA) | $43.22M | N/A | 68.5x | 0.0% | N/A | 0.0% | 0.00% |
| ProMIS Neurosciences Inc. (PMN) | $29.60M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Mural Oncology plc (MURA) | $35.38M | N/A | N/A | 0.0% | -173.6% | 0.0% | 0.00% |
| NextCure Inc (NXTC) | $29.31M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Peer median | $29.87M | N/A | 5.6x | 0.0% | -163.8% | -0.2% | 0.00% |
Similar Companies
These are the 12 companies most similar to MIRA Pharmaceuticals, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. The largest group, 9 of the 12, is in Biotechnology; the other 3 span 3 industries.
| Company | About | Peers |
|---|---|---|
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)Biotechnology | Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human... | TELO competitors |
| Scilex Holding Company (SCLX)Drug Manufacturers - General | Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. | SCLX competitors |
| TherapeuticsMD Inc (TXMD)Drug Manufacturers - Specialty & Generic | TherapeuticsMD, Inc. is a women's healthcare company in the United States. The company is headquartered in Boca Raton, Florida. | TXMD competitors |
| Mereo BioPharma Group PLC ADR (MREO)Biotechnology | Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops and markets therapeutic products for the treatment of oncology and rare diseases... | MREO competitors |
| INmune Bio Inc (INMB)Biotechnology | INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease... | INMB competitors |
| Marker Therapeutics Inc (MRKR)Biotechnology | Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based... | MRKR competitors |
| InspireMD Inc (NSPR)Medical Devices | InspireMD, Inc., a medical device company, is focused on the development and commercialization of proprietary MicroNet stent platform technology... | NSPR competitors |
| Plus Therapeutics Inc (PSTV)Biotechnology | Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing... | PSTV competitors |
| ImageneBio, Inc. (IMA)Biotechnology | ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. | IMA competitors |
| ProMIS Neurosciences Inc. (PMN)Biotechnology | ProMIS Neurosciences Inc. is a pioneering biotechnology company focused on the development of innovative therapeutic solutions for neurodegenerative diseases... | PMN competitors |
| Mural Oncology plc (MURA)Biotechnology | Mural Oncology plc is a pioneering biotechnology company dedicated to developing targeted therapies for solid tumors... | |
| NextCure Inc (NXTC)Biotechnology | NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other... | NXTC competitors |
Frequently Asked Questions About MIRA
Who are MIRA Pharmaceuticals, Inc. Common Stock's main competitors?
The companies most similar to MIRA Pharmaceuticals, Inc. Common Stock include Telomir Pharmaceuticals, Inc. Common Stock (TELO), Scilex Holding Company (SCLX), TherapeuticsMD (TXMD), Mereo BioPharma Group PLC ADR (MREO) and INmune Bio (INMB), listed from the closest match.
Who is MIRA Pharmaceuticals, Inc. Common Stock's biggest competitor?
Mereo BioPharma Group PLC ADR (MREO) is the largest of the similar companies at $49.11M; Telomir Pharmaceuticals, Inc. Common Stock (TELO) is the closest match by business profile, size, sector and industry.
How does MIRA stock compare with its competitors?
MIRA's net margin is 0.0% against a peer median of 0.0%.
Which of MIRA Pharmaceuticals, Inc. Common Stock's competitors pays a higher dividend?
MIRA Pharmaceuticals, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is MIRA Pharmaceuticals, Inc. Common Stock bigger than its competitors?
No. MIRA Pharmaceuticals, Inc. Common Stock is 9th by market cap among the 13 companies on this page; the largest is Mereo BioPharma Group PLC ADR (MREO) at $49.11M.
MIRA pages: Overview, Earnings, Forecast, Financials, Competitors